Bayesian Capital Management LP Buys New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Bayesian Capital Management LP bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 17,965 shares of the medical research company's stock, valued at approximately $3,316,000.

Other institutional investors have also recently made changes to their positions in the company. Fiduciary Financial Group LLC grew its position in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after purchasing an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares during the last quarter. Cornerstone Investment Partners LLC increased its position in shares of Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after acquiring an additional 69 shares during the last quarter. Metis Global Partners LLC lifted its holdings in Charles River Laboratories International by 4.4% during the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock worth $318,000 after acquiring an additional 72 shares during the period. Finally, Two Sigma Securities LLC boosted its position in Charles River Laboratories International by 4.3% in the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock worth $366,000 after purchasing an additional 81 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded down $1.26 during trading on Friday, hitting $140.10. The stock had a trading volume of 499,393 shares, compared to its average volume of 1,541,259. The firm has a market cap of $6.88 billion, a price-to-earnings ratio of 934.00, a P/E/G ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The business's 50-day moving average is $138.92 and its 200 day moving average is $166.78. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $2.27 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the firm's stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company's stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Birgit Girshick acquired 1,514 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on CRL. UBS Group reiterated a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Mizuho reduced their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 5th. Barclays upped their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research note on Thursday. Finally, Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a research note on Thursday. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $176.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).